Emgality was the third drug approved by the Food and Drug Administration (FDA) in a new class of drugs called calcitonin gene-related peptide (CGRP) blockers. Other CGRP antagonists are only approved for migraine prevention. However, unlike other drugs of this class, Emgality is also approved to treat cluster headaches.